Cytek Biosciences

CTKB

Valor de mercado US$ 682 mi

Cytek has expanded its Cytek® Cloud digital ecosystem with a new Cloud Analysis tool to create the industry's first end-to-end flow cytometry platform.

Investors need to pay close attention to CTKB stock based on the movements in the options market lately.

Cytek Biosciences, Inc. (CTKB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

FREMONT, Calif., and HAMBURG, Germany, Sept.

FREMONT, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- As clinical laboratories seek deeper cellular insights, greater efficiency, and more streamlined approaches to cell analysis, spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) will showcase its advanced solutions at two leading clinical cytometry events this fall: the European Society for Clinical Cell Analysis (ESCCA) 2026 Conference and ICCS 2026, the 41st Annual International Clinical Cytometry Meeting & Course.

FREMONT, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences.

FREMONT, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences,” “Cytek,” or the “Company”) (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that a jury in the United States District Court for the District of Delaware returned a verdict in the patent infringement action brought by Beckman Coulter, Inc. The jury found in Cytek's favor on three of the four asserted patent claims, finding noninfringement and invalidity as to each of those three claims. With respect to one claim, the jury found no literal infringement but found infringement under the doctrine of equivalents. The jury awarded past damages consisting of $20 million in lost profits and $36 million in royalties. Cytek intends to pursue post-verdict motions challenging the finding of infringement under the doctrine of equivalents and the related damages award.

Cytek Biosciences, Inc. (CTKB) Q2 2026 Earnings Call Transcript

Cytek Biosciences NASDAQ: CTKB reported second-quarter 2026 revenue growth of 6% year over year, supported by double-digit gains in the United States and China, while continued weakness in Europe and parts of Asia-Pacific limited overall growth.

Cytek Biosciences, Inc. (CTKB) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to earnings of $0.01 per share a year ago.